Clinicopathological Profile and FIGO Staging Pattern of Cervical Cancer in Postmenopausal Women Presenting with Bleeding
DOI:
https://doi.org/10.51168/fzrn4f05Cuvinte cheie:
Postmenopausal bleeding, Cervical cancer, FIGO staging, Squamous cell carcinoma, HistopathologyRezumat
Background:
Postmenopausal bleeding (PMB) requires prompt evaluation because it may indicate genital malignancy. This study assessed the etiological profile of PMB and the FIGO staging pattern of cervical cancer among postmenopausal women attending a tertiary care center.
Methods:
This hospital-based cross-sectional study was conducted at the Department of Obstetrics and Gynaecology, Rajendra Institute of Medical Sciences, Ranchi, from April 2021 to August 2022. Seventy-six postmenopausal women presenting with bleeding per vaginum were included. Clinical evaluation, Pap smear, and histopathological examination were performed as clinically indicated. Cervical cancer was staged according to the FIGO 2018 staging system. Data were analyzed using SPSS version 20.0.
Results:
The mean age of participants was 56 ± 7.3 years, with 47.4% aged 51–60 years. Parity ≥6 was reported in 30.3%, while 53.9% belonged to the low socioeconomic group. Hypertension was the most common comorbidity (32.9%). Malignant lesions were identified in 51.3% of participants and benign lesions in 48.7%. Squamous cell carcinoma of the cervix was the most frequent malignancy (42.1%). Among 34 cervical carcinoma cases, stage IIB was the most frequently reported stage (44.1%), followed by stages IIIB and IB (11.8% each).
Conclusion:
Cervical cancer was a frequent malignant cause of PMB in this study, with a substantial proportion of cases diagnosed at advanced stages.
Recommendation:
Strengthening awareness, timely evaluation of PMB, cervical cancer screening, and early referral may facilitate earlier diagnosis among postmenopausal women.
Referințe
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020. CA Cancer J Clin. 2021;71:209–249.
2. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer worldwide. Lancet Glob Health. 2020;8:e191–e203.
3. Indian Council of Medical Research. National Cancer Registry Programme Report 2020. ICMR; 2020.
4. Sankaranarayanan R, Basu P, Wesley RS, et al. Cervical cancer screening in India. Vaccine. 2008;26:S83–S92.
5. Burbos N, Musonda P, Giarenis I, et al. Predicting risk of endometrial cancer in PMB. BJOG. 2010;117:741–747.
6. Singh P, Dwivedi P, Goel A. PMB: A clinicopathological study. J Midlife Health. 2018;9:124–129.
7. Astrup K, Olivarius NF. PMB—diagnostic evaluation. BMJ. 2004;328:152–156.
8. Pecorelli S. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2009;105:107–108.
9. Murthy NS, Chaudhry K, Saxena S. Trends in cervical cancer incidence in India. Eur J Cancer Prev. 2005;14:513–519.
10. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2021;155:28–44.
11. Balasubramaniam G, Kulothungan V, Chaturvedi M, et al. Stage at diagnosis of cervical cancer in India. JCO Glob Oncol. 2020;6:481–491.
12. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in LMICs. Lancet Oncol. 2010;11:165–173.
13. Raychaudhuri S, Mandal S. Risk factors of cervical cancer. Asian Pac J Cancer Prev. 2012;13:2861–2866.
14. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. HPV and cervical cancer. Lancet. 2013;382:889–899.
15. Denny L, Anorlu R. Cervical cancer prevention and control. Int J Gynaecol Obstet. 2012;119:S17–S26.
Descărcări
Publicat
Număr
Secțiune
Licență
Copyright (c) 2026 Dr. Amrapali Kumari, Dr. Atima Bharti, Dr. Sonu Kumar, Dr. Rimjhim Kumari

TAceastă lucrare este licențiată în temeiul Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.














